Drug Trial Radar · NCT03881488
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
100
Actual
Start
May 17, 2019
Primary completion
May 21, 2025
Study completion May 21, 2025
Sponsor
- Lead sponsor
- Compass TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- IQVIA Pty Ltd; Merck, Sharp & Dohme, LLC, Rahway, NJ USA
- First posted
- Mar 19, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1, open-label, first-in-human study of CTX-471 administered as a monotherapy or in combination with pembrolizumab in patients with metastatic or locally advanced malignancies that have progressed while receiving an approved PD-1 or PD-L1 inhibitor. The study will be conducted in 2 treatment arms (Monotherapy Arm 1 and Combination Arm 2). Each arm will have two parts: Part 1 Dose Escalation and Part 2 Dose Expansion. In each arm (monotherapy and combination therapy), data from Part 1 (dose escalation) and Part 2 (dose expansion) were combined by dose level for reporting.
Conditions
- Locally Advanced Solid Tumor
- Metastatic Cancer
- Non-small Cell Lung Cancer
- Small Cell Lung Cancer
- Mesothelioma
- Melanoma
- Head and Neck Cancer
Interventions
CTX-471Drug
IV infusion every 2 weeks
Pembrolizumab (KEYTRUDA®)Drug
IV infusion every 6 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Dose Limiting Toxicities (DLTs), Treatment-emergent Adverse Events (TEAEs), and/or Changes in Clinical Laboratory AbnormalitiesTime frame: From first CTX-471 dose to 4 weeks after first dose for DLTs in monotherapy arms, to 6 weeks after first dose for DLTs in combination arms, to 60 days after last dose for TEAEs and clinical laboratory abnormalities in both monotherapy and combination arms
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Ocala Oncology Center
Ocala, Florida
Hematology Oncology Associates Of The Treasure Coast
Port Saint Lucie, Florida
Massachusetts General Hospital
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
Washington University School of Medicine, Siteman Cancer Center
St Louis, Missouri
Hackensack University Medical Center
Hackensack, New Jersey
Mt Sinai
New York, New York
Duke University School of Medicine
Durham, North Carolina
Institute for Translational Oncology Research (ITOR)
Greenville, South Carolina
Mary Crowley Cancer Research
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.